Product news

Share this article:
The FDA has broadened the US indication for Novartis' Reclast (zoledronic acid) once-yearly injection to include the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture. The FDA decision is based on safety and efficacy data from the “Recurrent Fracture Trial,” published in The New England Journal of Medicine. Trial results showed a 35% reduction in the risk of new clinical fractures in patients treated with Reclast, Novartis said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters